Exclusion Criteria:~* Known or identified cognitive disorder diagnosed previously by a physician, psychologist,
nurse-clinician, or other health care provider, or by StoP-AD staff~* Past or present use of a commercially
available acetyl-cholinesterase inhibitor including tacrine, donepezil, rivastigmine, or galantamine~* Past or
present use of memantine or other approved cognitive enhancement prescription agent~* History of heart disease,
myocardial infarction or documented acute coronary syndrome, or arrhythmia (including atrial fibrillation)~*
Corrected QT interval using Bazett's formula (QTcB) interval > 450 msec for males or 470 msec for females as
detected by EKG and confirmed by consultant cardiologist~* Clinically significant hypertension, anemia, liver
disease, or kidney disease, in opinion of a study physician (participants with treated hypertension who are
normotensive as a result of intervention may be enrolled.)~* Concurrent use of over-the-counter or prescription
medicines (e.g., tricyclic antidepressants, anti-histamines) known to prolong QTc interval, or to potentiate
the tendency of probucol to prolong this interval, in the opinion of a study physician~* Any inflammatory or
chronic pain condition that necessitates regular use of opiates (e.g., oxycodone, hydrocodone, tramadol,
meperidine, hydromorphone), or NSAIDs (more than 4 doses / week)~* Current plasma creatinine > 132 mmol/l (1.5
mg/dl)~* Current alcohol, barbiturate or benzodiazepine abuse or dependence (in opinion of study physician)~*
Any other medical condition that, in the opinion of a study physician, makes it inadvisable for the participant
to be assigned to regular dosage of probucol~* Enrolment in any trial or experimental protocol that, in the
opinion of a study physician, is likely to interfere with PREVENT-AD or any of its derivative protocols
including this one~* Any other condition that, in the opinion of a study physician, makes it medically
inappropriate for the participant to enroll in the program
